PMV PHARMACEUTICALS, INC. Payments to Acquire Marketable Securities
PMV PHARMACEUTICALS, INC. (PMVP) reported Payments to Acquire Marketable Securities of $37.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2026-06-30 was $26.73M, a 13.67% decline year-over-year.
- PMV PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2026-03-31 was $10.68M, a 32.12% decline year-over-year.
- PMV PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2025-12-31 was $21.04M, a 43.91% decline year-over-year.
- PMV PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2025-09-30 was $20.47M, a 48.04% decline year-over-year.
- PMV PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2025 was $88.20M, a 40.52% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2024 was $148.29M, a 32.76% decline from fiscal 2023.
- PMV PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2023 was $220.54M, a 3.78% decline from fiscal 2022.
- PMV PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2022 was $229.20M, a 10.76% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $37.40M 10-Q · filed 2026-08-14 | $58.45M derived: sum of 3 quarters · filed 2026-08-14 | $78.92M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $10.68M 10-Q · filed 2026-05-12 | $31.72M derived: sum of 2 quarters · filed 2026-05-12 | $52.19M derived: sum of 3 quarters · filed 2026-05-12 | $83.15M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $21.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $41.51M derived: sum of 2 quarters · filed 2026-03-06 | $72.48M derived: sum of 3 quarters · filed 2026-08-14 | $88.20M 10-K · filed 2026-03-06 |
| 2025-09-30 | $20.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $51.44M derived: sum of 2 quarters · filed 2026-08-14 | $67.16M 10-Q · filed 2025-11-12 | $104.67M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $30.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $46.69M 10-Q · filed 2026-08-14 | $84.20M derived: sum of 3 quarters · filed 2026-08-14 | $123.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $15.73M 10-Q · filed 2026-05-12 | $53.24M derived: sum of 2 quarters · filed 2026-05-12 | $92.64M derived: sum of 3 quarters · filed 2026-05-12 | $133.52M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $37.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $76.91M derived: sum of 2 quarters · filed 2026-03-06 | $117.80M derived: sum of 3 quarters · filed 2026-03-06 | $148.29M 10-K · filed 2026-03-06 |
| 2024-09-30 | $39.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $80.28M derived: sum of 2 quarters · filed 2025-11-12 | $110.77M 10-Q · filed 2025-11-12 | $144.16M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $40.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $71.37M 10-Q · filed 2025-08-07 | $104.77M derived: sum of 3 quarters · filed 2026-03-06 | $162.36M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | $30.49M 10-Q · filed 2025-05-09 | $63.88M derived: sum of 2 quarters · filed 2026-03-06 | $121.48M derived: sum of 3 quarters · filed 2026-03-06 | $227.53M derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $33.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $90.99M derived: sum of 2 quarters · filed 2026-03-06 | $197.04M derived: sum of 3 quarters · filed 2026-03-06 | $220.54M 10-K · filed 2026-03-06 |
| 2023-09-30 | $57.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $163.65M derived: sum of 2 quarters · filed 2024-11-07 | $187.15M 10-Q · filed 2024-11-07 | $221.83M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $106.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $129.55M 10-Q · filed 2024-08-08 | $164.24M derived: sum of 3 quarters · filed 2025-03-03 | $209.53M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $23.50M 10-Q · filed 2024-05-09 | $58.19M derived: sum of 2 quarters · filed 2025-03-03 | $103.48M derived: sum of 3 quarters · filed 2025-03-03 | $159.00M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $34.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $79.98M derived: sum of 2 quarters · filed 2025-03-03 | $135.49M derived: sum of 3 quarters · filed 2025-03-03 | $229.20M 10-K · filed 2025-03-03 |
| 2022-09-30 | $45.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $100.81M derived: sum of 2 quarters · filed 2023-11-09 | $194.51M 10-Q · filed 2023-11-09 | $216.19M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $55.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $149.22M 10-Q · filed 2023-08-09 | $170.90M derived: sum of 3 quarters · filed 2024-02-29 | $220.84M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $93.70M 10-Q · filed 2023-05-10 | $115.38M derived: sum of 2 quarters · filed 2024-02-29 | $165.33M derived: sum of 3 quarters · filed 2024-02-29 | $210.77M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $21.68M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $71.62M derived: sum of 2 quarters · filed 2024-02-29 | $117.07M derived: sum of 3 quarters · filed 2024-02-29 | $256.85M 10-K · filed 2024-02-29 |
| 2021-09-30 | $49.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $95.39M derived: sum of 2 quarters · filed 2022-11-08 | $235.17M 10-Q · filed 2022-11-08 | $235.17M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $45.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $185.22M 10-Q · filed 2022-08-09 | $185.22M derived: sum of 3 quarters · filed 2023-03-01 | $185.12M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $139.78M 10-Q · filed 2022-05-10 | $139.78M derived: sum of 2 quarters · filed 2023-03-01 | $139.67M derived: sum of 3 quarters · filed 2023-03-01 | $139.46M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$106.00K derived: sum of 2 quarters · filed 2023-03-01 | -$316.00K derived: sum of 3 quarters · filed 2023-03-01 | $14.51M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$316.00K derived: sum of 2 quarters · filed 2021-11-12 | $14.51M 10-Q · filed 2021-11-12 | $39.63M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $14.62M 10-Q · filed 2021-08-13 | $39.74M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2020-03-31 | $14.83M 10-Q · filed 2021-05-14 | $39.95M derived: sum of 2 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $25.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $43.45M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $18.33M 10-Q · filed 2020-11-13 | |||
| 2018-12-31 | $48.68M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |